NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market on Thursday that its fourth quarter revenues grew 45 percent year over year on an increase in revenues generated by its OVA1 ovarian cancer test.

For the three months ended Dec. 31, 2013, the Austin, Texas-based company recorded $1.6 million in total revenues, up from $1.1 million in the year-ago period. Product revenues, comprised of OVA1 sales, rose to $1.5 million from $1.0 million, while licensing revenues were flat at $113,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.